{"id":"nipocalimab-sc-liv","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FcRn is responsible for recycling and extending the half-life of immunoglobulins, particularly IgG. By blocking FcRn, nipocalimab reduces circulating levels of pathogenic antibodies, thereby decreasing autoimmune-mediated tissue damage. This mechanism is particularly relevant in antibody-mediated autoimmune diseases such as myasthenia gravis.","oneSentence":"Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:28.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized myasthenia gravis (gMG)"},{"name":"IgG-mediated autoimmune conditions"}]},"trialDetails":[{"nctId":"NCT04951622","phase":"PHASE3","title":"A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-07-15","conditions":"Myasthenia Gravis","enrollment":199}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nipocalimab SC-LIV","genericName":"Nipocalimab SC-LIV","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions. Used for Generalized myasthenia gravis (gMG), IgG-mediated autoimmune conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}